Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date: January 21, 2025
Subject: Disclosure of positive feedback from a Type C meeting with the U.S. Food & Drug Administration (FDA) regarding the APOLLO post-marketing confirmatory trial for bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
Key Financial Metrics
This filing is a current report regarding regulatory and clinical developments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Clinical Developments
The Company announced alignment with the FDA on the design of the APOLLO post-marketing confirmatory trial. Key features of the agreed-upon design include:
- Endpoints: Co-primary endpoints of average monthly total time in sunlight without pain (10:00–18:00) during the last month of treatment and percent change from baseline in whole blood metal-free protoporphyrin IX (PPIX) after 6 months.
- Dosing and Duration: Selection of a 60 mg dose of bitopertin with a 6-month treatment duration.
- Population: Inclusion of patients aged 12+ with EPP, including XLP.
- Study Design: Double-blind, placebo-controlled study with approximately 150 patients randomized 1:1.
- Scope: Sites in the United States, Canada, Europe, and Australia.
Guidance, Outlook, and Risks
Timeline and Outlook:
- Trial Initiation: Planned for mid-2025.
- NDA Submission: Anticipated in the second half of 2025 under the Accelerated Approval Program.
- Enrollment: Expected to be well underway by the Prescription Drug User Fee Act date for accelerated approval, if granted.
Risks and Contingencies:
The filing contains extensive forward-looking statements. Actual results may differ materially due to risks including the nature of the Company's strategy, timing of clinical data, and the possibility that clinical trial results may not support further development or marketing approval. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the specific terms of the FDA Type C meeting minutes regarding the APOLLO trial design.
- Monitor the actual initiation date of the APOLLO trial against the mid-2025 target.
- Track the Company's cash burn rate and liquidity position to assess runway for the 2025 NDA submission.
- Review the "Risk Factors" in the most recent Form 10-K and 10-Q for detailed regulatory and clinical risks.
- Confirm the final patient enrollment numbers and geographic distribution of trial sites once the study begins.